Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedMar 09, 2026
DataAggregated Company Financials
Companies15
  • 7D-6.9%
  • 3M7.5%
  • 1Y18.3%
  • YTD6.9%

Over the last 7 days, the Pharma industry has dropped 6.9%, driven by AstraZeneca declining 6.7%. In contrast, Nuformix has gained 15%. Over the past 12 months, the industry was up 18%. Earnings are forecast to grow by 9.6% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 09 Mar 2026UK£345.0bUK£90.6bUK£15.6b20.5x22.1x3.8x
Wed, 04 Feb 2026UK£332.3bUK£88.6bUK£14.5b23.7x23x3.8x
Fri, 02 Jan 2026UK£326.0bUK£89.3bUK£14.6b21.9x22.3x3.6x
Sun, 30 Nov 2025UK£327.4bUK£90.1bUK£14.7b21.7x22.2x3.6x
Tue, 28 Oct 2025UK£297.5bUK£88.1bUK£11.8b20.2x25.3x3.4x
Thu, 25 Sep 2025UK£269.1bUK£87.7bUK£11.7b18.4x23x3.1x
Sat, 23 Aug 2025UK£286.7bUK£87.4bUK£11.7b21.3x24.5x3.3x
Mon, 21 Jul 2025UK£253.3bUK£86.7bUK£10.7b26.7x23.8x2.9x
Wed, 18 Jun 2025UK£266.8bUK£86.7bUK£10.7b26.3x25.1x3.1x
Fri, 16 May 2025UK£255.4bUK£87.1bUK£10.7b26x23.8x2.9x
Sun, 13 Apr 2025UK£248.0bUK£87.2bUK£9.7b28.8x25.7x2.8x
Tue, 11 Mar 2025UK£290.9bUK£87.9bUK£9.6b29.2x30.2x3.3x
Thu, 06 Feb 2025UK£269.0bUK£86.8bUK£9.0b30.8x29.9x3.1x
Sat, 04 Jan 2025UK£226.4bUK£75.9bUK£7.8b31.4x28.9x3x
Mon, 02 Dec 2024UK£226.5bUK£74.7bUK£7.7b32x29.4x3x
Wed, 30 Oct 2024UK£245.8bUK£72.4bUK£9.1b29.2x27.1x3.4x
Fri, 27 Sep 2024UK£251.2bUK£71.2bUK£8.9b31.1x28.2x3.5x
Sun, 25 Aug 2024UK£275.7bUK£71.8bUK£8.9b41.6x30.8x3.8x
Tue, 23 Jul 2024UK£260.0bUK£70.8bUK£9.5b36.5x27.5x3.7x
Thu, 20 Jun 2024UK£265.1bUK£71.5bUK£9.6b30.8x27.7x3.7x
Sat, 18 May 2024UK£268.2bUK£71.5bUK£9.6b34.9x28x3.7x
Mon, 15 Apr 2024UK£248.1bUK£71.4bUK£9.8b33.2x25.4x3.5x
Wed, 13 Mar 2024UK£239.7bUK£70.2bUK£9.7b31.7x24.7x3.4x
Fri, 09 Feb 2024UK£226.3bUK£69.7bUK£9.6b34.6x23.5x3.2x
Sun, 07 Jan 2024UK£241.2bUK£68.9bUK£10.7b36x22.6x3.5x
Tue, 05 Dec 2023UK£229.9bUK£69.1bUK£10.7b34.1x21.5x3.3x
Thu, 02 Nov 2023UK£230.8bUK£70.8bUK£10.4b53.2x22.3x3.3x
Sat, 30 Sep 2023UK£247.2bUK£70.5bUK£10.4b76.3x23.8x3.5x
Mon, 28 Aug 2023UK£235.2bUK£69.4bUK£10.2b53.5x23x3.4x
Wed, 26 Jul 2023UK£236.8bUK£67.3bUK£7.8b52x30.2x3.5x
Fri, 23 Jun 2023UK£248.2bUK£67.7bUK£7.9b55.5x31.6x3.7x
Sun, 21 May 2023UK£257.1bUK£68.6bUK£8.0b56.6x32.3x3.7x
Tue, 18 Apr 2023UK£257.9bUK£69.5bUK£6.9b58.4x37.5x3.7x
Thu, 16 Mar 2023UK£232.5bUK£70.4bUK£7.0b44.6x33.4x3.3x
Price to Earnings Ratio

33.4x


Total Market Cap: UK£232.5bTotal Earnings: UK£7.0bTotal Revenue: UK£70.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 26.4x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.1x which is lower than its 3-year average PE of 26.4x.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 8.8% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-5.72%
Healthcare-6.80%
Pharma-6.88%
Pharma-6.88%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HCM HUTCHMED (China)UK£2.144.4%
+UK£77.8m		-10.1%PE5.4x
NFX NuformixUK£0.002712.2%
+UK£632.9k		223.5%PB7.7x
FUM Futura MedicalUK£0.0132.0%
+UK£145.3k		-90.2%PS0.9x

Latest News

HCM
UK£2.14
HUTCHMED (China)
7D
4.4%
1Y
-10.1%

HCM: Late-Stage Pipeline Progress Will Drive Future Re-Rating Potential

Analysts have trimmed their price target on HUTCHMED (China) to £3.51 from £3.62, reflecting updated assumptions that combine higher expected revenue growth with a lower profit margin profile and a richer forward P/E multiple. What's in the News Management issued consolidated earnings guidance for 2026, with Oncology/Immunology revenue expected in a range of US$330 million to US$450 million, giving investors a clearer view of the medium term revenue outlook (Corporate guidance).
GSK
UK£20.38
GSK
7D
-6.5%
1Y
30.8%
STX
UK£0.089
Shield Therapeutics
7D
-8.7%
1Y
169.7%

STX: Pediatric Expansion And China Filing Will Redefine Earnings Power

Analysts have lifted their price target for Shield Therapeutics to £0.14 from £0.10, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they view as better aligned with the company’s current outlook. What's in the News Shield Therapeutics filed and received acceptance of a Marketing Authorisation Application for ACCRUFeR with China’s National Medical Products Administration for adults with iron deficiency, supported by prior US FDA data and a Phase 3 study in Chinese adults with iron deficiency anemia and inflammatory bowel disease who are intolerant to oral ferrous products (Key Developments).
AGY
UK£0.12
Allergy Therapeutics
7D
-2.5%
1Y
76.9%
HIK
UK£12.09
Hikma Pharmaceuticals
7D
-3.2%
1Y
-42.9%

HIK: Leadership Change And Buyback Plan Will Support Future Re Rating Potential

Analysts have trimmed their price expectations for Hikma Pharmaceuticals, with our updated fair value moving from £21.82 to £20.47. This reflects recent cuts to Street targets to £2,000 and £1,600, as well as increased caution around growth, margins and the P/E investors may be willing to pay.
AZN
UK£145.00
AstraZeneca
7D
-4.9%
1Y
22.4%

AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook

The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.
EAH
UK£0.93
ECO Animal Health Group
7D
-9.3%
1Y
60.9%
HLN
UK£3.77
Haleon
7D
-5.7%
1Y
-5.2%
NFX
UK£0.0027
Nuformix
7D
12.2%
1Y
223.5%
FUM
UK£0.013
Futura Medical
7D
2.0%
1Y
-90.2%
ANCR
UK£2.74
Animalcare Group
7D
-2.1%
1Y
22.3%